On April 17, 2025, the global bleeding disorders community will come together to celebrate World Hemophilia Day. This year’s theme is “Access for all: Women and girls bleed too”. Today, women and girls with bleeding disorders (WGBDs) are still underdiagnosed and underserved. The global bleeding disorders community has the power—and the responsibility—to change this. Through recognition, diagnosis, treatment, and care, the quality of life of women and girls will improve, and the bleeding disorders community will become stronger.

This April, let’s celebrate our community and continue working towards a world where everyone—including woman and girls—has access to diagnosis, treatment, and comprehensive care.

Recognizing women and girls with bleeding disorders is a significant milestone for our community. In the past, they were often viewed solely as carriers rather than individuals with a bleeding disorder. It is time to fully embrace and acknowledge their experiences and struggles. Prioritizing the diagnosis and treatment of women and girls is crucial, and doing so strengthens our entire bleeding disorder community. Join us on April 17 to show your support for access for all—including women and girls. —Cesar Garrido, President, WFH

How to get involved

There are many ways you can help raise awareness about women and girls with bleeding disorders in your community—and globally. While the 2025 theme serves as a guide, feel free to tailor it to fit the needs of your region and organization. We will soon be sharing a variety of engagement options on our World Hemophilia Day webpage and the WFH News page. Additionally, make sure to follow the WFH social media channels—Facebook, X (Twitter), LinkedIn, and Instagram—for the latest World Hemophilia Day updates.

Learn more about World Hemophilia Day here.

The WFH would like to thank our 2025 World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., Biotest, CSL Behring, F. Hoffman-La Roche Ltd., Grifols, Kedrion, LFB S.A, Novo Nordisk, Octapharma, Pfizer, Regeneron, Sanofi, Sobi, and Takeda.